Premium
Time course of adverse events most commonly associated with topiramate for migraine prevention
Author(s) -
Láinez M. J. A.,
Freitag F. G.,
Pfeil J.,
Ascher S.,
Olson W. H.,
Schwalen S.
Publication year - 2007
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2007.01869.x
Subject(s) - topiramate , discontinuation , medicine , tolerability , placebo , adverse effect , nausea , anesthesia , migraine , randomized controlled trial , population , psychiatry , epilepsy , alternative medicine , pathology , environmental health
The efficacy, safety and tolerability of topiramate has been demonstrated in three large multicenter, randomized, double‐blind, placebo‐controlled trials. To characterize the time course of adverse events (AEs) that led to treatment discontinuation in ≥2% of patients who received topiramate 100 mg/day during three pivotal, multicenter, randomized, double‐blind, placebo‐controlled, and 26‐week trials. The pooled population comprised all randomized patients who reported safety data during the double‐blind phase (topiramate 100 mg/day, n = 386; placebo n = 372), which consisted of a 4‐week titration period and a 22‐week maintenance period. Incidence, time to onset, and cumulative mean rate of AEs were assessed. Overall, AEs led to treatment discontinuation in 24.9% of patients receiving topiramate 100 mg/day and 11.0% receiving placebo ( P < 0.001). AEs leading to discontinuation during the double‐blind phase in ≥2% of patients included paresthesia (8.0% discontinued), any cognitive symptoms (7.3% discontinued), fatigue (4.7% discontinued), insomnia (3.4% discontinued), nausea (2.3% discontinued), loss of appetite, anxiety, and dizziness (2.1% discontinued because each AE). Most AEs began during the titration period. Paresthesia, any cognitive symptoms, nausea, and loss of appetite occurred at a higher rate in the topiramate group than in the placebo group ( P < 0.01). AEs leading to discontinuation of topiramate are probably to occur during dose titration. If a patient has not experienced one of these AEs within the first 6 weeks of initiating topiramate 100 mg/day, these AEs are unlikely to occur.